Discover Products, Get Discovered.
Individuals find the right products. Businesses reach the right audience. One platform, free for both.
Individuals find the right products. Businesses reach the right audience. One platform, free for both.
Since 2020, Asia Africa Investment & Consulting has backed 4 African startups across 5 disclosed funding rounds totaling $55.2M, most heavily in Nigeria and Health Tech.
Asia Africa Investment & Consulting, often abbreviated as AAIC, is an investment and consulting firm based in Singapore. Its company information page lists a founding date of March 2008 and describes the business as focused on nurturing investments in emerging countries. The firm also maintains listed offices in Singapore, Tokyo, Shanghai, Gurugram, Nairobi, Lagos, Johannesburg, and Cairo. In Africa, AAIC has backed companies primarily in healthcare, with one fintech investment in the data provided. Its recorded activity spans April 2020 to November 2023 and includes six funding rounds totaling $56.1 million. The firm’s Africa portfolio in this record includes Helium Health, Waspito, RecoMed, and Rology in health tech, plus Zanifu in fintech. The rounds cover Venture, Pre-Series A, Series B, and other venture-stage financings, with activity in Nigeria, Cameroon, Kenya, South Africa, and Egypt.
Data updated · Aug 8, 2026
Asia Africa Investment & Consulting has backed 4 African startups across 5 disclosed funding rounds tracked on Liners, totaling $55.2M since 2020.
Mostly Venture Round: 2 of its 5 tracked rounds are at that stage, followed by Pre-Series A (1).
Its tracked rounds lean toward Health Tech (4), Fintech (1).
Asia Africa Investment & Consulting most often shares rounds with Global Ventures (2 shared deals), Ohara Pharmaceuticals (2 shared deals), DP World (1 shared deal).
The companies listed in the provided data are Waspito, Zanifu, Helium Health, RecoMed, and Rology. These deals span healthcare and fintech businesses across multiple African markets.
Yes. The provided record shows six funding rounds from April 2020 through November 2023, totaling $56.1 million. The largest listed round is Helium Health’s $30.0 million Series B in June 2023.